for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

China Resources Pharmaceutical Group Ltd

3320.HK

Latest Trade

3.82HKD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

3.68

 - 

5.89

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3.82
Open
--
Volume
--
3M AVG Volume
144.82
Today's High
--
Today's Low
--
52 Week High
5.89
52 Week Low
3.68
Shares Out (MIL)
6,282.51
Market Cap (MIL)
24,187.67
Forward P/E
6.31
Dividend (Yield %)
3.12

Next Event

Full Year 2021 China Resources Pharmaceutical Group Ltd Earnings Release

Latest Developments

更多

China Resources Pharmaceutical Sees 9-Mth Net Profit Attributable For Dong-E-E-Jiao To Range From RMB281.09 Mln-RMB316.34 Mln

Immunotech Biopharm & China Resources Pharmaceutical Enter Strategic Cooperation Framework Deal

China Resources Pharmaceutical Says Li Xiangming Ceased To Be Exec Director, Vice Chairman

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About China Resources Pharmaceutical Group Ltd

CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED is a Hongkong-based investment holding company. The Company, along with its subsidiaries, is principally engaged in the research and development, manufacturing, distribution and retail of pharmaceutical and other healthcare products. The Company mainly operates through three segments. Pharmaceutical Manufacturing segment is engaged in the research and development, manufacturing and sale of pharmaceutical and other healthcare products. Pharmaceutical Distribution segment is engaged in the provision of distribution solutions to pharmaceutical manufacturers and dispensers, such as hospitals and other medical institutions, distributors and retail pharmacies. Pharmaceutical Retail segment is involved in the operation of retail pharmacies in China and Hongkong.

Industry

Major Drugs

Contact Info

Room 4104-05, 41F,China Resources Buldng

No. 26, Harbour Road, Wan Chai

Hong Kong

+852.null.25938991

http://www.crpharm.com/

Executive Leadership

Chuncheng Wang

Non-Executive Chairman of the Board

Yuewei Han

Chief Executive Officer, Executive Director

Jingwen Weng

Chief Financial Officer, Vice President, Executive Director

Yi Feng

Chairman of CR Double-Crane

Dengfeng Gao

Vice secretary and the President of Dong-E-E-Jiao

Key Stats

2.11 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, HKD)

2018

189.7K

2019

204.5K

2020

200.4K

2021(E)

234.5K
EPS (HKD)

2018

0.640

2019

0.520

2020

0.520

2021(E)

0.611
Price To Earnings (TTM)
7.66
Price To Sales (TTM)
0.11
Price To Book (MRQ)
0.50
Price To Cash Flow (TTM)
2.89
Total Debt To Equity (MRQ)
146.00
LT Debt To Equity (MRQ)
11.34
Return on Investment (TTM)
10.43
Return on Equity (TTM)
2.68

Latest News

Latest News

《股市简讯》永泰生物获华润医药入股,盘初涨逾8%至逾一个月高位

* 拥有央企背景的华润医药周二晚间公告,与Yue Cheng International Capital等卖方订立协议,将购入其所持永泰生物合共约5,146万股普通股,占已发行股本总额的10%。

沪综指收创逾一周新低 受美股大跌及经济增长担忧拖累

中国股市沪综指周一收创逾一周新低。分析师表示,上周五美股再次大跌,加之周末公布的经济数据不及预期,今日大盘低开后弱势震荡,成交量略有回升,但仍维持在较低水平。近期市场对宏观经济预期不乐观,相对谨慎的心态令场内交易难以活跃。

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up